KALA BIO, Inc. (KALA)

Every figure this model derived for KALA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2020-09-30
cash 7,229,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 10,582,000 AssetsCurrent 2026-06-30
current liabilities 1,538,000 LiabilitiesCurrent 2026-06-30
equity 9,044,000 StockholdersEquity 2026-06-30
interest expense 3,276,000 InterestExpenseNonoperating 2025-12-31
ocf -19,863,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 0 RevenueFromContractWithCustomerIncludingAssessedTax 2025-12-31
sbc 1,838,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up KALA on one particular measure came for.

RatioValue
current ratio6.88
current ratio reported6.88
dilution pct114.76
interest cover-6.41
roic-913.48

What to be careful about

What this model itself distrusts about KALA's figures. Written by the derivation as it ran, not added afterwards.